Prilosec ❲Verified Source❳
The following overview of (active ingredient omeprazole ) synthesizes clinical data, pharmacological mechanisms, and market history. 1. Introduction and Overview
: Used in combination with antibiotics (e.g., amoxicillin and clarithromycin) to treat Helicobacter pylori infections. prilosec
Prilosec is a widely used medication in the class of . It was first patented in 1978 and approved for medical use in 1988. Originally marketed as Losec , its name was changed to Prilosec in the U.S. to avoid confusion with the diuretic Lasix. It is available both as a prescription and over-the-counter (OTC) medication. 2. Indications and Usage The following overview of (active ingredient omeprazole )
: As a delayed-release capsule, it is acid-labile and must be protected from gastric juice; it is usually absorbed in the small intestine. Peak plasma concentrations occur 1–3 hours after oral dosing. Prilosec is a widely used medication in the class of
: Some studies link long-term PPI use to an increased risk of bone fractures.
: While its plasma half-life is short (less than 1 hour), its inhibitory effect on acid secretion lasts much longer because the binding to the proton pump is covalent. Full therapeutic effects often take 1 to 4 days to develop. 5. Safety and Adverse Effects
The following overview of (active ingredient omeprazole ) synthesizes clinical data, pharmacological mechanisms, and market history. 1. Introduction and Overview
: Used in combination with antibiotics (e.g., amoxicillin and clarithromycin) to treat Helicobacter pylori infections.
Prilosec is a widely used medication in the class of . It was first patented in 1978 and approved for medical use in 1988. Originally marketed as Losec , its name was changed to Prilosec in the U.S. to avoid confusion with the diuretic Lasix. It is available both as a prescription and over-the-counter (OTC) medication. 2. Indications and Usage
: As a delayed-release capsule, it is acid-labile and must be protected from gastric juice; it is usually absorbed in the small intestine. Peak plasma concentrations occur 1–3 hours after oral dosing.
: Some studies link long-term PPI use to an increased risk of bone fractures.
: While its plasma half-life is short (less than 1 hour), its inhibitory effect on acid secretion lasts much longer because the binding to the proton pump is covalent. Full therapeutic effects often take 1 to 4 days to develop. 5. Safety and Adverse Effects
